If You'd Held VTI Through Every Recession Since 2001, Here's Exactly How Much You'd Have Today
Key PointsThere have been three recessions and four bear markets over the past 25 years.
Aggregator
iFixit dismantles Apple's Duo: 'You'd better baby that screen'
Battery replacement gets the thumbs up, but it all hinges on dust. A conventional phone might be better bet for home repairers
Prudential plc Repurchases Ordinary Shares and Reports 2,465,982,262 Total Voting Rights
Prudential plc announced that it has purchased ordinary shares of 5 pence each from JP Morgan Securities plc under arrangements announced on 6 January 2026 and 2 September 2026. Between 19 October 2026 and 23 October 2026, the Company repurchased shares on the XLON trading venue,
Prudential plc Repurchases Ordinary Shares and Reports 2,465,982,262 Total Voting Rights
Prudential plc announced that it has purchased ordinary shares of 5 pence each from JP Morgan Securities plc under arrangements announced on 6 January 2026 and 2 September 2026. Between 19 October 2026 and 23 October 2026, the Company repurchased shares on the XLON trading venue,
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial
BioNTech SE (Nasdaq: BNTX, “BioNTech”) and DualityBiologics (Suzhou) Co., Ltd. (“DualityBio”, HKEX: 9606.HK) announced today that the DYNASTY-Breast02 global Phase 3 clinical trial (NCT06018337) met its primary endpoint demonstrating a statistically signif
HUTCHMED Announces Positive Phase III Data for ORPATHYS plus TAGRISSO in SAFFRON and SANOVO Lung Cancer Trials
HUTCHMED (China) Limited announced positive results from the SAFFRON global Phase III trial. The combination of ORPATHYS plus TAGRISSO demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival and overall survival versus doub
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial
BioNTech SE (Nasdaq: BNTX, “BioNTech”) and DualityBiologics (Suzhou) Co., Ltd. (“DualityBio”, HKEX: 9606.HK) announced today that the DYNASTY-Breast02 global Phase 3 clinical trial (NCT06018337) met its primary endpoint demonstrating a statistically signif
HUTCHMED Announces Positive Phase III Data for ORPATHYS plus TAGRISSO in SAFFRON and SANOVO Lung Cancer Trials
HUTCHMED (China) Limited announced positive results from the SAFFRON global Phase III trial. The combination of ORPATHYS plus TAGRISSO demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival and overall survival versus doub
These 2 Words Were the Driving Force for Warren Buffett’s Success
How did Buffett become arguably the most successful investor in history? Time and control.
What Lula’s Win Means for Brazil’s Markets, Currency
Nur Cristiani, head of Latin America investment strategy at JPMorgan Private Bank, examines the market implications of the Brazilian election after President Luiz Inácio Lula da Silva pulled off a stunning comeback to defeat Flávio Bolsonaro, the right-wing candidate that many investors preferred. She speaks on “Bloomberg Surveillance.” (Source: Bloomberg)
Venezuelan opposition leader makes surprise return home
Venezuelan opposition leader Maria Corina Machado makes a surprise return home after nearly a year in exile.
FTSE 100 Advances As Bank, Mining Stocks Climb Higher
(RTTNews) - The U.K. stock market gained moderate ground in positive territory on Monday, supported by gains in bank, mining and technology stocks.
FTSE 100 Advances As Bank, Mining Stocks Climb Higher
(RTTNews) - The U.K. stock market gained moderate ground in positive territory on Monday, supported by gains in bank, mining and technology stocks.
Sachem Capital - Preferred Stock Price Target Increased by 17.03% to $29.39
The average one-year price target for Sachem Capital - Preferred Stock (NYSEAM:SACH.PRA) has been revised to $29.39 / share. This is an increase of 17.03% from the prior estimate of $25.11 dated June 8, 2026.
Sachem Capital - Preferred Stock Price Target Increased by 17.03% to $29.39
The average one-year price target for Sachem Capital - Preferred Stock (NYSEAM:SACH.PRA) has been revised to $29.39 / share. This is an increase of 17.03% from the prior estimate of $25.11 dated June 8, 2026.
Coffee Prices Fall Despite Decline in ICE Coffee Inventories to 5-week Low
December arabica coffee (KCZ26 ) closed down -5.00 (-1.60%) on Friday, and November ICE robusta coffee (RMX26 ) closed down -60 (-1.82%). Arabica coffee prices fell on Friday due to (1) some long liquidation pressure after the rally seen in mid-October, and (2) ideas that ICE inventories may rise over...
Cocoa Prices Close Mildly Higher Despite 2.5-year High in ICE Inventories
December ICE NY cocoa (CCZ26 ) closed +10 (+0.18%) on Friday, and December ICE London cocoa #7 (CAZ26 ) closed up +17 (+0.41%). NY cocoa prices closed higher on Friday despite rising ICE cocoa inventories. ICE cocoa inventories have steadily increased since the start of the year, climbing to a...
Coffee Prices Fall Despite Decline in ICE Coffee Inventories to 5-week Low
December arabica coffee (KCZ26 ) closed down -5.00 (-1.60%) on Friday, and November ICE robusta coffee (RMX26 ) closed down -60 (-1.82%). Arabica coffee prices fell on Friday due to (1) some long liquidation pressure after the rally seen in mid-October, and (2) ideas that ICE inventories may rise over...
Cocoa Prices Close Mildly Higher Despite 2.5-year High in ICE Inventories
December ICE NY cocoa (CCZ26 ) closed +10 (+0.18%) on Friday, and December ICE London cocoa #7 (CAZ26 ) closed up +17 (+0.41%). NY cocoa prices closed higher on Friday despite rising ICE cocoa inventories. ICE cocoa inventories have steadily increased since the start of the year, climbing to a...
Suicide attempts, ideation spiked significantly among older U.S. adults after COVID-19 pandemic
New research from UCLA Health and UC San Diego Health found a significant spike in suicidal thoughts, planning and attempts among older U.S. adults in the years following the COVID-19 pandemic.